Sat.May 27, 2023 - Fri.Jun 02, 2023

article thumbnail

FDA warns patients about compounded versions of Novo Nordisk's Ozempic, Wegovy

Fierce Pharma

FDA warns patients about compounded versions of Novo Nordisk's Ozempic, Wegovy kdunleavy Wed, 05/31/2023 - 13:02

FDA 340
article thumbnail

Retailers Are Making a Big Push Into Healthcare. Is Our Sector Ready?

MedCity News

While retailers already have a customer service focus, there is a steep learning curve to healthcare and the nuances of how things operate. It will be critical that these brands do their due diligence and invest in innovations that work to improve the fundamentals of healthcare such as efficient provider credentialing and flexible and sustainable working practices for providers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Big Pharma inventory management trends revealed

European Pharmaceutical Review

The inventory position of 28 major pharmaceutical manufacturers in 2022 has been revealed in an annual report. Analysis explored the impact of macro-trends on inventory management from corporate reports of Big Pharma companies including Merck, AstraZeneca and Pfizer. It investigated how excessive inventories are affecting the industry and what factors could influence inventory growth in 2023.

Pharma 88
article thumbnail

UK’s NICE recommends Pfizer’s rimegepant to treat migraine

Pharmaceutical Technology

The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of Pfizer ’s rimegepant (Vydura) to prevent migraine attacks. The therapy has been recommended as an option to prevent episodic migraines in adult patients, who have between four and 15 migraine attacks per month, and where a minimum of three preventive treatments have previously failed.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

AZ, Merck's Lynparza wins FDA nod in prostate cancer subgroup following advisory committee vote

Fierce Pharma

After a panel of independent experts endorsed a narrow approval for AstraZeneca and Merck’s Lynparza in metastatic castration-resistant prostate cancer (mCRPC), the FDA has followed suit. | The drug is now approved to treat BRCA-mutated metastatic castration-resistant prostate cancer in combination with Johnson & Johnson’s Zytiga and a corticosteroid.

FDA 305

More Trending

article thumbnail

Reframing Mental Health Awareness Month

InCrowd

Happy Mental Health Awareness Month! But wait… is it really happy? What does mental health awareness truly mean? I’ve always struggled with the idea of dedicating a single month to a specific cause. While it’s important to de-stigmatize mental illness and endeavor to provide mental health organizations with desperately needed funding, I worry that awareness will wane the moment this month ends?

article thumbnail

Janssen submits NDA to FDA for PAH combination therapy

Pharmaceutical Technology

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a new drug application (NDA) for its investigational single-tablet combination therapy of macitentan 10mg and tadalafil 40mg (M/T STCT) to the US Food and Drug Administration (FDA), to treat pulmonary arterial hypertension (PAH). The company is seeking approval for the combination therapy for the long-term treatment of PAH in adult patients with World Health Organisation functional class II-III.

FDA 98
article thumbnail

Look out, GSK. Pfizer has its adult RSV vaccine approval and is raring to launch

Fierce Pharma

About a month after GSK won the world's first approval for a respiratory syncytial virus (RSV) vaccine, rival Pfizer has followed suit. | After winning FDA approvals one month apart, Pfizer and GSK are set to launch competing RSV vaccines this fall.

FDA 269
article thumbnail

Burnout Continues To Crush Clinicians, But Voice Tech and AI Could Help

MedCity News

In addition to reducing workload, NLP and ambient voice technology can also improve the quality of care that clinicians provide. By analyzing EHRs and other patient data, NLP algorithms can identify potential health risk factors and recommend preventative measures.

Patients 112
article thumbnail

Pencil-on-Paper Wearable Sensor

Medgadget

Researchers at Penn State have developed a low-cost, wearable sensor using pencil-on-paper technology. This approach involves depositing graphite (pencil ‘lead’) on paper that has been treated with sodium chloride, to create a conductive, low-cost sensor. Previously, these researchers had developed such sensors to detect moisture and even used them to develop a smart diaper ( yes, really ).

article thumbnail

SNIPR targets antibiotic resistance with CRISPR-based gene therapy trial

Pharmaceutical Technology

The Danish CRISPR biotech SNIPR BIOME has released the first glimpse at the safety profile for SNIPR001, a gene therapy intended to target antibiotic resistance. Interim clinical results from a Phase I trial have demonstrated SNIPR001’s safety in healthy volunteers. Additionally, E.Coli was detected in a dose-dependent manner in feces, suggesting the therapy’s proof-of-principle targetin and removing the bacteria, including antibiotic-resistant strains.

article thumbnail

Alnylam sticks with aggressive litigation strategy against Pfizer and Moderna, filing yet another patent lawsuit

Fierce Pharma

Alnylam sticks with aggressive litigation strategy against Pfizer and Moderna, filing yet another patent lawsuit zbecker Tue, 05/30/2023 - 10:24

296
296
article thumbnail

A Father’s Vision for New Kind of Gene Therapy Leads to a $100M Financing

MedCity News

Ray Therapeutics’ gene therapy is independent of the causative genes driving inherited vision disorders, which CEO Paul Bresge says is important for reaching a broad patient population. Rare disease retinitis pigmentosa is the first disease target, but the startup also plans to test its approach in more prevalent eye disorders.

Leads 111
article thumbnail

A REVIEW OF MAGNETIC NANOPARTICLES IN TARGETED DRUG DELIVERY

Pharmatutor

A REVIEW OF MAGNETIC NANOPARTICLES IN TARGETED DRUG DELIVERY admin Mon, 05/29/2023 - 15:04 About Authors CHETNA MODI 1 *, VINIT MODI 2 , SHWETA RAY 2 , PIYUSH NARIYA 2 , VARSHA GADHVI 2 1 Professor, Department of Pharmaceutics, Anand Pharmacy College, Anand, Gujarat, India. 2 Research Scholar, Department of Pharmaceutics, Anand Pharmacy College, Anand, Gujarat, India. * chetnamodi306@gmail.

article thumbnail

Stealth and Pharmanovia partner for commercialisation of elamipretide

Pharmaceutical Technology

Stealth BioTherapeutics has made an exclusive licensing agreement with Pharmanovia for the commercialisation of its elamipretide to treat Barth syndrome. Pharmanovia will hold exclusive rights for the commercialisation of elamipretide in the EU, other European countries including Switzerland, Norway, Iceland and the UK, and the Middle East and northern Africa region.

FDA 98
article thumbnail

Former Novartis execs cleared of Greek bribery charges after yearslong investigation

Fierce Pharma

After a yearslong investigation involving politicians and medical professionals alike, Novartis is looking to close the books on its Greek bribery imbroglio. | After an investigation that dates back to 2017, four former Novartis executives and a Greek politician were cleared of bribery charges. But 15 doctors were charged for their alleged involvement.

Doctors 258
article thumbnail

After FDA Miss in Diabetes, Lexicon Lands Long-Awaited Approval in Heart Failure

MedCity News

Lexicon Pharmaceuticals drug Inpefa is now FDA-approved for heart failure. Inpefa is third in its class, but the biotech says its pill can reach a specific subset of patients, enabling it to stand apart from rival medicines from AstraZeneca and partners Eli Lilly and Boehringer Ingelheim.

FDA 107
article thumbnail

A glimpse into public perception of mental health care in the United States

Clarify Health

Addressing the mental health crisis in the United States is a complex undertaking, due to multiple factors contributing to prevalence and severity of several conditions. Recent findings from the Clarify Health Institute highlight these growing problems and speak to a need for action to combat this crisis. According to its most recent research brief, “The Kids Are Not Alright: Mental Health Utilization Among Children and Young Adults, 2016-2022,” hospital admissions for mental illnes

article thumbnail

US companies drive 2023 drug launches positioned for blockbuster success by 2028

Pharmaceutical Technology

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut.

Pharma 101
article thumbnail

ASCO: Novartis pressures Lilly with Kisqali, targeting $3B opportunity in early breast cancer

Fierce Pharma

Adding Kisqali to endocrine therapy after surgery reduced the risk of invasive tumor recurrence or death by 25% in certain early-stage breast cancers.

244
244
article thumbnail

Strive Health Rakes In $166M for Value-based Kidney Care

MedCity News

Strive Health’s $166 million funding round was led by NEA and included participation from CVS Health Ventures, CapitalG, Echo Ventures, Town Hall Ventures, Ascension Ventures and Redpoint. In total, the company has raised more than $400 million.

102
102
article thumbnail

CHMP meeting highlights – May 2023

European Pharmaceutical Review

A neurosteroid drug was one of two medicines recommended for approval at the Committee for Medicinal Products for Human Use (CHMP) ’s May 2023 meeting. Ztalmy (ganaxolone) received a positive opinion for epileptic seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. This genetic condition is defined by seizures starting during infancy.

article thumbnail

Amplo Biotechnology receives NIH-NIAMS grant for gene therapy AMP-201

Pharmaceutical Technology

Amplo Biotechnology has received a fast track phase I/II STTR grant from the NIH-NIAMS [National Institutes of Health’s National Institute of Arthritis and Musculoskeletal and Skin Diseases] for its gene therapy AMP-201. The company will receive substantial funding to advance AAV-ColQ gene therapy. AMP-201 addresses the severe congenital myasthenic syndrome (CMS) caused by collagen Q (ColQ) deficiency.

article thumbnail

Carrying blockbuster sales expectations, BMS' Camyzos picks up early nod from England's NICE

Fierce Pharma

As Bristol Myers Squibb braces for increasing generic competition this decade, the company is counting on its newer medicines to drive growth. | As Bristol's top-sellers creep toward the patent cliff, new launch Camzyos has picked up a key endorsement in England.

Medicine 179
article thumbnail

Digital Health Funding Steadied in Q1 After a Year of Decline

MedCity News

Global funding for digital health companies finally stabilized in Q1 of this year. The sector raised $3.4 billion — this marks the first time the digital health world didn’t experience a quarter-over-quarter funding decline since Q4 of 2021. By holding steady, digital health startups defied the dwindling fundraising totals seen across the broader venture capital landscape, where funding dropped by 13% quarter-over-quarter.

104
104
article thumbnail

CRISPR-based microbial gene therapy delivers promise

European Pharmaceutical Review

The novel CRISPR-Cas therapeutic selectively targets antibiotic-resistant E. coli which can cause life-threatening bloodstream infections” Positive interim results from a Phase I trial have demonstrated that the first CRISPR-armed phage microbial gene therapy can reduce Escherichia coli ( E. coli ) levels in the GI tract. “With the combined killing effects of bacteriophages and CRISPR-Cas technology, SNIPR001 has demonstrated the ability to target and eliminate antibiotic-resistant E

article thumbnail

Lexicon gets FDA approval for Inpefa to treat heart failure

Pharmaceutical Technology

Lexicon Pharmaceuticals (Lexicon) has received approval from the US Food and Drug Administration (FDA) for its Inpefa drug to treat heart failure. Inpefa is a once-daily oral tablet indicated as an inhibitor of sodium-glucose co-transporter type 2 (SGLT2) and type 1 (SGLT1). It is intended to lower the risk of cardiovascular death, urgent heart failure visit, and hospitalisation for heart failure.

FDA 98
article thumbnail

Lexicon finally scores FDA nod for heart failure drug Inpefa

Fierce Pharma

Lexicon finally scores FDA nod for heart failure drug Inpefa kdunleavy Tue, 05/30/2023 - 05:46

FDA 279
article thumbnail

Pfizer Hemophilia Drug Reduces Bleeding in Key Study; Regulatory Filings Are Planned

MedCity News

Marstacimab, a Pfizer drug for both hemophilia A and B, met the main goal of a Phase 3 study and the company now plans to discuss the data with regulators. The Pfizer drug could beat to the market a Novo Nordisk drug that addresses the same novel target.

Marketing 104
article thumbnail

Lonza to acquire Synaffix to strengthen ADC development

PharmaTimes

Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services - News - PharmaTimes

86
article thumbnail

AION Labs and BioMed X launch sixth challenge for AI-driven drug discovery

Pharmaceutical Technology

Last week, artificial intelligence (AI) innovator AION Labs called for applications for its latest AI-powered startup. In partnership with BioMed X, the Israeli company hopes to attract top talent from across the globe to develop an AI platform capable of discovering new high-affinity small molecules. Launched back in 2021, AION Labs was formed as an alliance between AstraZeneca , Merck , Pfizer and Teva , as well as Amazon and the Israel Biotech Fund.

Pharma 84
article thumbnail

Persistent Sun Pharma ready to complete Taro buyout—16 years after initial offer

Fierce Pharma

Persistent Sun Pharma ready to complete Taro buyout—16 years after initial offer kdunleavy Tue, 05/30/2023 - 09:57

Pharma 251
article thumbnail

Interoperability: Past, Present, and Future

MedCity News

A new decentralized network of the future exists and is in operation today. Large payers and providers are already beginning to use it for administrative transactions, although clinical transactions are also envisioned.